2nd Annual CMOD Canadian Biomarkers and Surrogate Endpoints Meeting
“Biomarkers and Personalized Medicine”
May 17, 2010
Banting Theatre, Health Canada Campus - Tunney’s Pasture, Ottawa, Ontario
Opening Remarks and Introduction
The Personalized Medicine Landscape - Clarissa Desjardins, CEPMED
Rewards and Risks of Using Biomarkers in Drug Development - Agnes Klein, Health Canada
CIHR Initiatives - Advancing Research and Practice - Peter Liu, CIHR/ U Toronto
Streamlining drug development and clinical trials with biomarkers - J-C Tardif, Montreal Heart
GWAS, Sequencing and Integrative Biology - John Rioux, Montreal Heart Institute
Pharmacogenomics: A Research Prospective- Michael Phillips, Montreal Heart Institute
PANEL DISCUSSION
Novel Approaches and Clinical Utility - Peter Libby, Harvard Medical School
Clopidogrel and Genetic Variance - Jessica Mega, Brigham and Women’s Hospital
Hepatic Safety - Brian Foster, Health Canada
Providing Personalized Medicine with Molecular Imaging - Donald Black, CMOD
Case studies: Pharma / Diagnostic
Science Policy Perspectives from the Health Portfolio - Narayanan Iyer, Health Canada
Panel Discussion
Patient Selection Strategies for the Development of MDM2 Inhibitors - Robert Wasserman
Opportunities and Challenges of Rx-Dx Co-Development - Helen Wu, Roche
What is Required to Ensure a Smooth Transition From an R&D Test to a Test Used Within a Clinical Environment? - Patrice Hugo, Clearstone
How can Canada lead in the adoption of personalized medicine strategies?
Conclusion and Adjourn